Expression and clinical significance of calumenin in brain gliomas

• DOI: 10.3760/cma.j.issn.1001-2346.2020.02.005
• Publication Date: 2020-02-28
• Authors: Peng Kang; Chuanbao Zhang; Linhao Yuan; Jiayi Peng; Yangyang Wang; Wang Jia; Ke Qian
• Keywords: Isocitrate dehydrogenase; Clinical Significance

Objective To detect the expression of calumenin (CALU) in human brain glioma samples, to explore its effect on patient′s outcome, and analyze related biological functions genes co-expressed with CALU.

Methods A retrospective analysis was conducted CALU sequencing clinical data 288 patients positive mRNAseq_325 database Chinese Glioma Genome Atlas (CGGA). We analyzed effects levels survival different types patients. The multivariate Cox regression method used determine relevant factors affecting Pearson correlation employed screen their were explored using online bioinformatic tools.

Results Among patients, 4.74±0.68, 5.49±1.12 6.17±0.94 World Health Organization (WHO) grade Ⅱ, Ⅲ, Ⅳ respectively, 6.13±1.17 5.08±0.76 isocitrate dehydrogenase l (IDH1) wild-type IDH1 mutant gliomas 5.79±0.07 4.71±0.07 1p/19q non-codeletion co-deletion. comparative differences above indicators statistically significant (all P 0.05). median high low (144 cases each) 13.0(1-132)months 82.5(2-149)months, which had difference (P<0.01). In WHO Ⅱ-Ⅳ gliomas, mainly reduced time Ⅲ (both P<0.01). showed that an independent factor influencing (RR=2.193, 95%CI: 1.507-3.192, CGGA database, there 325 positively correlated expression. those signal transduction, cell adhesion cellular metabolism, involved endoplasmic reticulum protein processing, cancer pathways.

Conclusion CALU is significantly malignancy may serve as prognostic thus provides a potential therapeutic target future research.

Key words: Glioma; Gene expression; Prognosis; Calumenin